Information Library

Results for: Capital - Phase II/III - Central Laboratories

In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions.  Search our library today.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Intarcia and Quintiles Finalize Innovative Alliance

    Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).

  • Quintiles Launches China CRO, Kun Tuo

    Press Release — December 13, 2011 – Further deepening its commitment to China, Quintiles announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.

  • PharmAsia News Article Reprint

    Media Coverage — March 1, 2010
    Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News.

  • QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS

    Press Release — September 24, 2009 - Quintiles Transnational Corp. announced the opening of an expanded regional facility near Edinburgh, Scotland; space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management.

Page 1 of 1 (4 results)

Subscribe to Email Based on Your Interests

Set preferences